After-hours movers: Apple gains on surprise beat, Lyft tumbles
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
Citi Comments on Apellis Pharmaceuticals (APLS), Moves PT to $106
May 5, 2023 11:15 AM EDTCiti analyst Yigal Nochomovitz raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $106.00 (from $88.00) while maintaining a Buy rating.
The analyst comments "The first quarter of any drug launch is frequently a wildcard. Syfovre embodied this uncertainty given 1) mid-1Q23 approval, 2) temporary J-code,... More
